Behold.ai vs Oxipit (2026)
These two sit at the autonomous end of imaging AI, both removing normal studies from human review entirely, both CE or UK marked and neither cleared for autonomous use in the US. So the buyer's real question is who stands behind an auto reported study that no clinician read. If you want the cleanest published autonomy evidence and CT head coverage, start with Behold.ai, but read its continuity history first. If corporate stability and the first ever autonomous reporting clearance matter more, start with Oxipit, now owned by the imaging IT vendor Sectra. Behold's original entity entered administration in early 2025 and a successor acquired the assets. Oxipit was acquired intact. Both publish strong operating detail; the difference is who will still be there.
- The cleanest published autonomy evidence at this frontier: peer reviewed work reporting 15 percent of chest X-rays auto reported normal at a 0.33 percent error rate, publishing the auto report rate and its error rate together, which is what a defensible autonomy claim requires.
- CT head as well as chest X-ray: it removes more than 60 percent of CT head scans from the reporting workload at a 93 percent negative predictive value, coverage Oxipit's autonomous product does not match.
- A concrete commercial benchmark: it positions explicitly against outsourced radiology reporting, so a buyer can price it against the per study outsourcing rate it displaces.
- The first regulatory approval anywhere for autonomous diagnostic reporting: ChestLink holds CE Class IIb across 32 European countries, and the company publishes the fullest operating detail in the category, over a year of supervised operation on more than 500,000 images at a 99 percent sensitivity threshold, with an audit trail.
- Stable corporate footing: acquired by the imaging IT vendor Sectra in April 2026, so procurement, roadmap, and support run through an established organization rather than a relaunched entity.
- A broader safety netted suite: 75 findings plus a quality module that continuously re checks AI negative studies, a standing false negative control.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Behold.ai and Oxipit are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
UK company whose red dot platform sits at the autonomous end of imaging AI: it reports chest X-rays it classifies as High Confidence Normal autonomously, removing them from the radiologist worklist (about 15 percent of studies, according to the company), triages suspected lung cancer for urgent reporting, and has a companion CT head product. Work published in Clinical Radiology reported a 0.33 percent error rate on the auto reported studies and a 60 percent reduction in missed lung cancers when triage ran alongside consultant radiologists.
Source: AI Health Index, July 2026
Lithuanian radiology AI developer based in Vilnius, part of Sectra, the enterprise imaging company, since 2026. Its ChestLink product, which the company describes as the world's first autonomous AI medical device, holds CE Class IIb certification to identify normal chest X-rays and issue final reports on them with no radiologist involved; the company states that autonomous operation is available in Europe and not in the United States, and no FDA clearance is listed for any of its products.
Source: AI Health Index, July 2026
Questions buyers ask
How do Behold.ai and Oxipit work with the EHR?
For Behold.ai, the how it works page states that after analysis it sends an electronic notification back to the trust RIS, or to PACS where reporting is PACS driven, marking each examination as normal or abnormal and prioritizing it in the existing worklist; for auto reported studies that notification is the report.
With Oxipit, the DICOM conformance statement (6 November 2024) covers ChestLink 1.0 and ChestEye 2.6 as a storage provider and user, including Basic Text SR, secondary capture, presentation state and encapsulated PDF objects. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How are Behold.ai and Oxipit priced and sold?
In Behold.ai's case, the original company entered administration in January 2025 after failing to win NHS AI Diagnostic Fund contracts, NICE withdrew the product from its recommendations the following month, and a successor acquired the assets and relaunched it.
The packaging and the seller are public: Oxipit sells three suites (the CXR Suite with ChestLink and ChestEye, the CT Suite and the MSK Suite) through a contact route on its site, and since 2026 it has been part of Sectra, so contracting and support may run through the parent. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How do Behold.ai and Oxipit handle patient data?
With Behold.ai, the how it works page states that images reach the platform over an encrypted VPN and that all patient examination data resides in fully NHS accredited data centers.
In Oxipit's case, the ChestLink user manual (software version 1.0, 9 March 2023) says anonymization is set up by enabling the anonymization options in the customer's archive, which "ensures that no sensitive personal data is processed by ChestLink". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Which settings and specialties do Behold.ai and Oxipit cover?
For Behold.ai, the settings on record are NHS trust radiology departments.
With Oxipit, the ChestLink user manual states the indication: adults aged 18 and over who can stand for an erect posteroanterior chest radiograph, with AP images and children excluded; autonomous reporting covers the studies ChestLink is confident have no actionable finding, in Europe. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both sit at the autonomous frontier and remove normal studies from human review, so the governing questions are accountability and subgroup performance, and neither publishes demographic subgroup analysis, the pointed gap when a tool removes studies from review entirely, since any group the model underperforms on disproportionately receives an unread scan.
Neither is available for autonomous use in the United States; Oxipit is CE only and Behold's autonomous operation is a UK and European deployment, with its FDA clearance covering triage only. Behold's regulatory standing is unsettled: NICE withdrew red dot in February 2025 after the original company entered administration, and a buyer must verify which authorizations, support terms, and indemnity transferred to the successor entity. Behold's materials do not address who holds clinical responsibility for an auto reported study no clinician read. Neither publishes pricing or a security attestation.